Bristol-Myers v. Biocraft
Executive Summary
Bristol-Myers received a preliminary injunction prohibiting Biocraft from marketing its generic cefadroxil antibiotic on Feb. 28, Bristol announced in a same-day release. Newark Federal Court Judge Dickenson Debevoise determined that the generic product would infringe on Bristol-Myers' crystalline cefadroxil monohydrate patent, due to expire in 2002. Bristol-Myers is seeking a full trial in order to obtain a permanent injunction. Biocraft has 90 days to appeal the ruling to the U.S. Court of Appeals.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.